Golimumab: a guide to its use in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis


    loading  Checking for direct PDF access through Ovid

Abstract

Subcutaneous golimumab improved the signs and symptoms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in large, well designed, phase III trials. It also improved physical function and health-related quality of life and was generally well tolerated. Adapted from Biodrugs 2009; 23 (2): 125-35.[1]

    loading  Loading Related Articles